493 related articles for article (PubMed ID: 31524529)
1. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
2. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
3. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
Adams OJ; Stanczak MA; von Gunten S; Läubli H
Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
[TBL] [Abstract][Full Text] [Related]
4. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
5. Targeting glyco-immune checkpoints for cancer therapy.
Manni M; Läubli H
Expert Opin Biol Ther; 2021 Aug; 21(8):1063-1071. PubMed ID: 33502268
[No Abstract] [Full Text] [Related]
6. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.
Stanczak MA; Siddiqui SS; Trefny MP; Thommen DS; Boligan KF; von Gunten S; Tzankov A; Tietze L; Lardinois D; Heinzelmann-Schwarz V; von Bergwelt-Baildon M; Zhang W; Lenz HJ; Han Y; Amos CI; Syedbasha M; Egli A; Stenner F; Speiser DE; Varki A; Zippelius A; Läubli H
J Clin Invest; 2018 Nov; 128(11):4912-4923. PubMed ID: 30130255
[TBL] [Abstract][Full Text] [Related]
7. Viewing Siglecs through the lens of tumor immunology.
Fraschilla I; Pillai S
Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
[TBL] [Abstract][Full Text] [Related]
8. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
9. Siglec and anti-Siglec therapies.
Murugesan G; Weigle B; Crocker PR
Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
[TBL] [Abstract][Full Text] [Related]
10. Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.
Haas Q; Markov N; Muerner L; Rubino V; Benjak A; Haubitz M; Baerlocher GM; Ng CKY; Münz C; Riether C; Ochsenbein AF; Simon HU; von Gunten S
Front Immunol; 2022; 13():996746. PubMed ID: 36211376
[TBL] [Abstract][Full Text] [Related]
11. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
[TBL] [Abstract][Full Text] [Related]
12. Tools to study and target the Siglec-sialic acid axis in cancer.
Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
[TBL] [Abstract][Full Text] [Related]
13. Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy.
Wielgat P; Rogowski K; Niemirowicz-Laskowska K; Car H
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575400
[TBL] [Abstract][Full Text] [Related]
14. Human sialoglycan ligands for immune inhibitory Siglecs.
Gonzalez-Gil A; Li TA; Kim J; Schnaar RL
Mol Aspects Med; 2023 Apr; 90():101110. PubMed ID: 35965135
[TBL] [Abstract][Full Text] [Related]
15. The sialoglycan-Siglec-E checkpoint axis in dexamethasone-induced immune subversion in glioma-microglia transwell co-culture system.
Wielgat P; Czarnomysy R; Trofimiuk E; Car H
Immunol Res; 2019 Oct; 67(4-5):348-357. PubMed ID: 31741237
[TBL] [Abstract][Full Text] [Related]
16. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
17. Siglec receptors as new immune checkpoints in cancer.
Stanczak MA; Läubli H
Mol Aspects Med; 2023 Apr; 90():101112. PubMed ID: 35948467
[TBL] [Abstract][Full Text] [Related]
18. Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.
Fan T; Liao Q; Zhao Y; Dai H; Song S; He T; Wang Z; Huang J; Zeng Z; Guo H; Zhang H; Qiu X
Cancer Sci; 2023 Feb; 114(2):370-383. PubMed ID: 36310398
[TBL] [Abstract][Full Text] [Related]
19. Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands.
Boelaars K; van Kooyk Y
Trends Cancer; 2024 Mar; 10(3):230-241. PubMed ID: 38160071
[TBL] [Abstract][Full Text] [Related]
20. Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy.
Rodrigues Mantuano N; Natoli M; Zippelius A; Läubli H
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
